Merck KGAA, Pfizer, and Syndax enter ovarian cancer trial collaboration
Merck KGAA, Pfizer Inc., and Syndax Pharmaceuticals Inc. entered into an agreement to explore a combination of the anticancer therapies avelumab and entinostat for patients with heavily pre-treated recurrent ovarian cancer.
- Trial Collaborations
- R&D (No Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com